Nelum is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address significant unmet clinical needs, particularly in the areas of fibrosis and various forms of cancer. Their lead drug candidate, NLM-001, is a small molecule Hedgehog inhibitor that has been in-licensed from Takeda, previously known as TAK-441. Currently, NLM-001 is undergoing Phase IB-IIA clinical trials for pancreatic cancer, having demonstrated a safe profile in earlier Phase I trials. Additionally, the compound is being investigated for its potential efficacy in treating fibrotic conditions, including pulmonary, liver, and skin fibrosis.

The company's commitment to advancing its pipeline reflects a strategic focus on creating best-in-class patented molecules. By targeting critical pathways involved in cancer and fibrosis, Nelum aims to provide effective treatment options for patients suffering from these challenging conditions. The ongoing clinical trials for NLM-001 signify the company's dedication to bringing innovative therapies to market that can significantly improve patient outcomes in areas with high unmet medical needs.

United States

Nelum is a clinical stage biopharmaceutical company developing first in class and best in class patented molecules. Our area of focus is different forms of cancer.

Our first drug, NLM-001, is a best in class small molecule hedgehog inhibitor currently in a phase Ib-IIa clinical trial in pancreatic cancer, after showing a safe profile in the Phase I trial.

Nelum

Company Details